Development of a model for nerve agent inhalation in conscious rats

Toxicology Mechanisms and Methods

Volumn 23, Issue 7, 2013, Pages 537-547

  Wong, Benjamin ^a   Perkins, Michael W ^a   Santos, Mariton D ^a   Rodriguez, Ashley M ^a   Murphy, Gleeson ^a   Sciuto, Alfred M ^a  

^a US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

Author keywords

Chemical warfare; Cholinesterases; Inhalation exposure; Nerve agents; Organophosphates; Vapor

Indexed keywords

ACETYLCHOLINESTERASE; CHEMICAL WARFARE AGENT; DYFLOS; NITROGEN;

AMBIENT AIR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CHEMICAL WARFARE; CONTROLLED STUDY; DEFECATION; DOSE RESPONSE; ENVIRONMENTAL STRESS; FASCICULATION; LACRIMATION; LUNG LAVAGE; LUNG PARENCHYMA; LUNG TOXICITY; MALE; MICTURITION; NONHUMAN; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RAT; SALIVATION; TIDAL VOLUME; TOXIC INHALATION; WEIGHT REDUCTION;

ACETYLCHOLINESTERASE; ANIMALS; CHEMICAL WARFARE AGENTS; INHALATION EXPOSURE; MALE; MODELS, BIOLOGICAL; PLETHYSMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84883315800     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2013.796033     Document Type: Article

References (39)

1. Abbas F. (1984). Report of the specialists appointed by the Secretary-General of the United Nations to investigate allegations by the Islamic Republic of Iran concerning the use of chemical weapons. Arch Belg Suppl:302-10.
2. Alexander DJ, Collins CJ, Coombs DW, et al. (2008). Association of Inhalation Toxicologists (AIT) working party recommendation for standard delivered dose calculation and expression in non-clinical aerosol inhalation toxicology studies with pharmaceuticals. Inhal Toxicol 20:1179-89.
3. Anthony JS, Haley M, Manthei J, et al. (2004). Inhalation toxicity of Cyclosarin (GF) vapor in rats as a function of exposure concentration and duration: potency comparison to sarin (GB). Inhal Toxicol 16: 103-11.
4. Anzueto A, Berdine GG, Moore GT, et al. (1986). Pathophysiology of soman intoxication in primates. Toxicol Appl Pharmacol 86:56-68.
5. Atchison CR, Sheridan RE, Duniho SM, Shih TM. (2004). Development of a Guinea pig model for low-dose, long-term exposure to organophosphorus nerve agents. Toxicol Mech Meth 14:183-94.
6. Bajgar J. (2004). Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv Clin Chem 38: 151-216.
7. Benton BJ, McGuire JM, Sommerville DR, et al. (2006). Effects of whole-body VX vapor exposure on lethality in rats. Inhal Toxicol 18: 1091-9.
8. Bide RW, Armour SJ, Yee E. (2000). Allometric respiration/body mass data for animals to be used for estimates of inhalation toxicity to young adult humans. J Appl Toxicol 20:273-90.
9. Broughton E. (2005). The Bhopal disaster and its aftermath: a review. Environmental Health: A Global Access Science Source 4:6.
10. Dabisch PA, Davis EA, Renner JA, et al. (2008). Biomarkers of low-level exposure to soman vapor: comparison of fluoride regeneration to acetylcholinesterase inhibition. Inhal Toxicol 20:149-56.
11. Dunn MA, Sidell FR. (1989). Progress in medical defense against nerve agents. J Am Med Assoc 262:649-52.
12. Eckerman I. (2005). The Bhopal gas leak: analyses of causes and consequences by three different models. J Loss Prevent Process Indust 18:213-17.
13. Ellman GL, Courtney KD, Andres Jr V, Feather-Stone RM. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95.
14. Fawcett WP, Aracava Y, Adler M, et al. (2009). Acute toxicity of organophosphorus compounds in guinea pigs is sex-and age-dependent and cannot be solely accounted for by acetylcholinesterase inhibition. J Pharmacol Exp Therapeut 328:516-24.
15. Feakes D. (2003). Global civil society and chemical and biological warfare. In Kaldor M, Anheier H, Glasius M, eds. Global civil society yearbook 2003. London, UK: LSE Global Governance.
16. Flegal KM, Carroll MD, Ogden CL, Curtin LR. (2010). Prevalence and trends in obesity among us adults, 1999-2008. J Am Med Assoc 303: 235-41.
17. Franz DR, Hilaski R. (1990). Sequence of cardiorespiratory effects of soman altered by route of administration. Toxicology Lett 51:221-5.
18. Gupta RC, Patterson GT, Dettbarn WD. (1985). Mechanisms involved in the development of tolerance to DFP toxicity. Fund Appl Toxicol 5: S17-28.
19. Guyton AC. (1947). Measurement of the respiratory volumes of laboratory animals. Am J Physiol 150:70-7.
20. Haigh JR, Lefkowitz LJ, Capacio BR, et al. (2008). Advantages of the WRAIR whole blood cholinesterase assay: comparative analysis to the micro-Ellman, Test-mate ChE, and Michel (DeltapH) assays. Chem Biol Interact 175:417-20.
21. Kirby RD, ed. (2005). Potential military chemical/biological agents and compounds. Washington, D.C.: Dept. of the Army.
22. Maynard RL, Chilcott RP. (2009). Toxicology of chemical warfare agents. In Ballantyne B, Marrs TC, Syversen T, eds. General and applied toxicology. 3rd ed. Hoboken (NJ): John Wiley and Sons Limited.
23. Mioduszewski R, Manthei J, Way R, et al. (2002a). Interaction of exposure concentration and duration in determining acute toxic effects of sarin vapor in rats. Toxicol Sci 66:176-84.
24. Mioduszewski RJ, Manthei JH, Way RA, et al. (2002b). Low-level sarin vapor exposure in rats: effect of exposure concentration and duration on pupil size [online]. Ft. Belvoir: Defense Technical Information Center. Available from: http://handle.dtic.mil/100.2/ADA402869 [last accessed 13 May 2013].
25. Muse WT, Thomson S, Crouse C, Matson K. (2006). Generation, sampling, and analysis for low-level GB (Sarin) and GF (Cyclosarin) vapor for inhalation toxicology studies. Inhal Toxicol 18:1101-8.
26. Niven AS, Roop SA. (2004). Inhalational exposure to nerve agents. Respir Care Clin N Am 10:59-74.
27. Phalen RF. (1976). Inhalation exposure of animals. Environ Health Perspect 16:17-24.
28. Redemann CE, Chaikin SW, Fearing RB, et al. (1948). The vapor pressures of forty-one fluorine-containing organic compounds. J Am Chem Soc 70:3604-6.
29. Rickett DL, Glenn JF, Beers ET. (1986). Central respiratory effects versus neuromuscular actions of nerve agents. Neurotoxicol 7:225-36.
30. Shih ML, McMonagle JD, Dolzine TW, Gresham VC. (1994). Metabolite pharmacokinetics of soman, sarin and GF in rats and biological monitoring of exposure to toxic organophosphorus agents. J Appl Toxicol 14:195-9.
31. Shih TM, Kan RK, McDonough JH. (2005). In vivo cholinesterase inhibitory specificity of organophosphorus nerve agents. Chem Biol Interact 157-8:293-303.
32. Sidell FR, Borak J. (1992). Chemical warfare agents: II. Nerve agents. Ann Em Med 21:865-71.
33. Sidell FR, Takafuji ET, Franz DR. (1997). Medical aspects of chemical and biological warfare. Washington (DC), Falls Church (VA), Fort Sam Houston (TX), Fort Detrick, Frederick (MD), Bethesda (MD): Borden Institute, Office of the Surgeon General, United States Army Medical Department Center and School; United States Army Medical Research and Material Command; Uniformed Services University of the Health Sciences.
34. Smithson AE, Levy L-A, Henry L. Stimson Center. (2000). Ataxia: the chemical and biological terrorism threat and the US response. Washington, DC: Henry L. Stimson Center.
35. Terry Jr AV, Buccafusco JJ, Gearhart DA, et al. (2011). Repeated, intermittent exposures to diisopropylfluorophosphate in rats: protracted effects on cholinergic markers, nerve growth factor-related proteins, and cognitive function. Neuroscience 176:237-53.
36. U.S. Census Bureau. (2010). Age and sex composition: 2010 census briefs. Washington, D.C.: U.S. Government Printing Office.
37. Vijayaraghavan R, Schaper M, Thompson R, et al. (1993). Characteristic modifications of the breathing pattern of mice to evaluate the effects of airborne chemicals on the respiratory tract. Arch Toxicol 67: 478-90.
38. Villa AF, Houze P, Monier C, et al. (2007). Toxic doses of paraoxon alter the respiratory pattern without causing respiratory failure in rats. Toxicology 232:37-49.
39. Wecker L, Kiauta T, Dettbarn WD. (1978). Relationship between acetylcholinesterase inhibition and the development of a myopathy. J Pharmacol Exp Ther 206:97-104.